BioShin Raises $60 Million to Bring Biohaven's Drugs to China
September 29, 2020 at 05:05 AM EDT
BioShin Limited of Shanghai raised $60 million in a Series A financing to develop Biohaven's clinical portfolio of neurological drugs in China . BioShin, a subsidiary of Biohaven, remains majority owned by Biohaven after the transaction. In Q4, BioShin will start a China/Korea Phase III trial of Nurtec™ ODT (rimegepant) for acute migraine. Also in Q4, it will begin a China arm of a global Phase III trial of troriluzole in Spinocerebellar Ataxia (SCA). The A round was led by OrbiMed. More details.... Share this with colleagues: // //
